Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IDXX
IDXX logo

IDXX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
572.200
Open
572.200
VWAP
562.50
Vol
476.64K
Mkt Cap
44.18B
Low
555.185
Amount
268.11M
EV/EBITDA(TTM)
28.92
Total Shares
78.88M
EV
44.96B
EV/OCF(TTM)
37.16
P/S(TTM)
10.15
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
Show More

Events Timeline

(ET)
2026-05-05
06:50:00
FY26 Consensus Revenue Growth View Raised to 8.6%-10.6%
select
2026-05-05
06:40:00
IDEXX Reports Q1 Revenue of $1.14B, Exceeding Expectations
select
2026-04-01 (ET)
2026-04-01
05:20:00
Idexx Laboratories Launches Cancer Dx Panel in the UK
select

News

seekingalpha
9.5
05-05seekingalpha
IDEXX Laboratories Q1 2026 Earnings Call Highlights
  • Significant Revenue Growth: IDEXX reported a 14% year-over-year revenue increase and an 11% organic growth in Q1 2026, with earnings per share at $3.47, reflecting the company's strong performance driven by innovation and a global customer base.
  • Strong Instrument Sales: CAG instrument revenues saw a 28% organic growth, primarily due to the strong sales of 1,100 IDEXX inVue Dx analyzers, indicating the company's increasing competitiveness in the high-end diagnostic equipment market.
  • International Market Expansion: The successful launch of Cancer Dx for canine lymphoma in Europe and Australia, with nearly 70% of tests run as part of a panel in North America, marks IDEXX's further penetration into global markets.
  • Optimistic Future Outlook: IDEXX raised its full-year revenue guidance for 2026 to between $4.675 billion and $4.760 billion, with expected earnings per share between $14.45 and $14.90, demonstrating management's confidence in future performance.
seekingalpha
9.5
05-05seekingalpha
IDEXX Laboratories Q1 Earnings Beat Expectations
  • Earnings Beat: IDEXX reported Q1 GAAP EPS of $3.47, exceeding expectations by $0.06, indicating sustained profitability and competitive strength in the market.
  • Significant Revenue Growth: The company achieved revenue of $1.14 billion, a 14.2% year-over-year increase, surpassing market expectations by $30 million, demonstrating strong product demand, particularly in the CAG Diagnostics segment.
  • 2026 Revenue Guidance Raised: IDEXX increased its 2026 revenue guidance to $4.675 billion to $4.76 billion, exceeding market consensus by $420 million, with expectations that CAG Diagnostics will drive continued growth, boosting investor confidence.
  • EPS Outlook Upgraded: The company raised its 2026 EPS outlook to $14.45 to $14.90, reflecting a $0.13 increase from prior guidance midpoint, supported by optimistic expectations for revenue growth and comparable operating margin expansion.
seekingalpha
9.5
05-04seekingalpha
IDEXX Laboratories to Announce Q1 Earnings on May 5
  • Earnings Announcement Date: IDEXX Laboratories is set to announce its Q1 2023 earnings on May 5 before market open, with a consensus EPS estimate of $3.41, reflecting a 17.2% year-over-year increase, which could further solidify its profitability in the industry.
  • Revenue Expectations: The anticipated revenue for Q1 is $1.11 billion, representing an 11.2% year-over-year growth, indicating that the company is maintaining strong sales performance amidst growing market demand, potentially attracting more investor interest.
  • Historical Performance Review: Over the past two years, IDEXX has exceeded EPS estimates 100% of the time and revenue estimates 75% of the time, providing confidence to investors and showcasing the company's financial health.
  • Expectation Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 3 downward revisions, while revenue estimates experienced 4 upward revisions and 1 downward revision, reflecting varying market perceptions of the company's future performance, which may influence investor decisions.
CNBC
9.5
04-23CNBC
Dover Reports Strong Q1 Results with Double-Digit Earnings Growth
  • Significant Revenue Growth: Dover's Q1 revenue rose 10% year-over-year to $2.05 billion, exceeding the LSEG consensus of $2 billion, indicating strong market performance and robust customer demand.
  • Surge in Orders: The company reported a 24% year-over-year increase in orders to $2.5 billion, signaling strong market demand and effective order fulfillment capabilities, which further boosts investor confidence in Dover's future performance.
  • Improved Profitability: Adjusted earnings per share (EPS) reached $2.28, beating expectations by 2 cents and reflecting an 11.2% increase from the previous year, showcasing the company's success in cost control and operational efficiency.
  • Optimistic Market Outlook: Dover anticipates over $1 billion in revenue by 2026 from AI and power infrastructure applications, representing 11.5% of total revenue, highlighting the company's strategic positioning and growth potential in emerging markets.
Yahoo Finance
5.0
04-11Yahoo Finance
IDEXX Launches Canine Cancer Detection Panel in the UK
  • Early Detection Innovation: IDEXX's newly launched cancer detection panel in the UK is specifically designed for early detection of lymphoma in at-risk dogs, providing results within 3 to 5 business days, which addresses a critical clinical need and is expected to significantly enhance diagnostic efficiency for veterinarians.
  • Strong Market Demand: Data indicates that 71% of UK pet owners have expressed interest in cancer screening for their pets, reflecting robust market demand for this test and further driving IDEXX's market share growth in the veterinary field.
  • Significant Technical Advantages: The panel offers 79% sensitivity and 99% specificity, enabling classification of B-cell and T-cell phenotypes while also allowing monitoring of patients during chemotherapy, thereby enhancing veterinarians' decision-making capabilities in cancer management.
  • Future Expansion Plans: IDEXX plans to expand the panel's capabilities over the next three years to cover the majority of canine cancer cases, further solidifying its leadership position in proactive veterinary cancer management and intervention.
Newsfilter
9.5
04-08Newsfilter
IDEXX Laboratories Schedules Q1 2026 Financial Results Release
  • Earnings Release Schedule: IDEXX Laboratories has scheduled the release of its Q1 2026 financial results for May 5, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
  • Analyst Conference Call: The company will host an analyst conference call at 8:30 AM ET on the same day, providing an interactive opportunity for investors to gain insights into the company's performance and build confidence.
  • Webcast Access: Investors can access the live webcast and Q1 2026 Earnings Snapshot through the IDEXX website, ensuring broad dissemination and availability of information, which enhances the company's transparency.
  • Global Impact: As a leader in pet healthcare innovation, IDEXX is dedicated to supporting the veterinary community through its diagnostic and software products, advancing medical care and improving efficiency, thereby reinforcing its significant position in the industry.
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
BofA
Neutral
downgrade
$790 -> $660
AI Analysis
2026-05-05
Reason
BofA
Price Target
$790 -> $660
AI Analysis
2026-05-05
downgrade
Neutral
Reason
BofA lowered the firm's price target on Idexx Laboratories to $660 from $790 and keeps a Neutral rating on the shares. The firm sees today's Q1 beat as "demonstrating solid execution in tough markets," but is left with questions on both macro durability and the pace of inVue placements through the balance of the year given the still-challenging macro backdrop and Q1 inVue placements coming in a bit lighter than expected, the analyst tells investors.
UBS
Andrea Alfonso
Neutral
downgrade
$730 -> $640
2026-04-28
Reason
UBS
Andrea Alfonso
Price Target
$730 -> $640
2026-04-28
downgrade
Neutral
Reason
UBS analyst Andrea Alfonso lowered the firm's price target on Idexx Laboratories to $640 from $730 and keeps a Neutral rating on the shares. The Q1 earnings outlook is cautious amid softer macro conditions and declining vet visit trends, though U.S. pet results are expected to hold up, the analyst tells investors in a research note. The firm is "less confident" Idexx can preserve its outlook for the full-year given the tough consumer backdrop.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IDXX
Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 40.32, compared to its 5-year average forward P/E of 49.42. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
49.42
Current PE
40.32
Overvalued PE
61.29
Undervalued PE
37.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
34.42
Current EV/EBITDA
27.61
Overvalued EV/EBITDA
42.49
Undervalued EV/EBITDA
26.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.01
Current PS
8.83
Overvalued PS
13.43
Undervalued PS
8.60

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

us stocks
Intellectia · 40 candidates
Moving Average Relationship: PriceAboveMA20Month Price Change Pct: $0.00 - $20.00Is Index Component: GSPC, RUT, DJI, NDXOne Week Rise Prob: >= 60One Week Predict Return: >= 4.0%
Ticker
Name
Market Cap$
top bottom
IDXX logo
IDXX
IDEXX Laboratories Inc
46.80B
VERA logo
VERA
Vera Therapeutics, Inc
3.03B
DCGO logo
DCGO
DocGo Inc
64.06M
SLQT logo
SLQT
SelectQuote Inc
137.12M
JJSF logo
JJSF
J&J Snack Foods Corp
1.53B
INFU logo
INFU
InfuSystem Holdings Inc
213.65M
top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
what is a good buy right now
Intellectia · 32 candidates
Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: 15.0% - 100.0%Target Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC, NDXOne Week Rise Prob: 60 - 100One Week Predict Return: 0.0% - 100.0%
Ticker
Name
Market Cap$
top bottom
TPR logo
TPR
Tapestry Inc
26.06B
BK logo
BK
Bank of New York Mellon Corp
81.14B
TTD logo
TTD
Trade Desk Inc
13.04B
GPN logo
GPN
Global Payments Inc
18.87B
MDB logo
MDB
MongoDB Inc
27.39B
MA logo
MA
Mastercard Inc
492.21B
which stock price above $100 but bearish
Intellectia · 61 candidates
Price: >= $100.00Option Sentiments: Bearish
Ticker
Name
Market Cap$
top bottom
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.69T
MA logo
MA
Mastercard Inc
473.76B
GE logo
GE
General Electric Co
335.96B
KLAC logo
KLAC
KLA Corp
199.72B
BLK logo
BLK
BlackRock Inc
183.61B
GEV logo
GEV
GE Vernova Inc
181.21B

Whales Holding IDXX

A
Amundi Luxembourg S.A.
Holding
IDXX
+17.56%
3M Return
K
KBC Asset Management NV
Holding
IDXX
+10.47%
3M Return
P
Performance Wealth Partners, LLC
Holding
IDXX
+10.29%
3M Return
L
Los Angeles Capital Management LLC
Holding
IDXX
+9.29%
3M Return
W
William Blair Investment Management, LLC
Holding
IDXX
+9.02%
3M Return
R
Railways Pension Trustee Company Limited
Holding
IDXX
+9.00%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 560.11 USD — it has decreased -2.11

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 1.14B USD, increased 14.26

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 3.52 USD, increased 18.92

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of May 11 2026.

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 44.18B USD.